Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Kathrin Heinrich, Swantje Held, Arndt Stahler, Annabel Helga Sophie Alig, Ivan Jelas, Jobst C. von Einem, Sebastian Stintzing, Clemens Giessen-Jung, Dominik P. Modest

Open source

DOI: 10.3389/fonc.2022.751453
Published: 2022-02-18
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.751453,
  title = {Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial},
  author = {Annika Kurreck and Volker Heinemann and Ludwig Fischer von Weikersthal and Thomas Decker and Florian Kaiser and Jens Uhlig and Michael Schenk and Jens Freiberg-Richter and Bettina Peuser and Claudio Denzlinger and Ullrich Graeven and Kathrin Heinrich and Swantje Held and Arndt Stahler and Annabel Helga Sophie Alig and Ivan Jelas and Jobst C. von Einem and Sebastian Stintzing and Clemens Giessen-Jung and Dominik P. Modest},
  year = {2022},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2022.751453},
  url = {https://doi.org/10.3389/fonc.2022.751453}
}

RIS

TY  - JOUR
TI  - Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial
AU  - Annika Kurreck
AU  - Volker Heinemann
AU  - Ludwig Fischer von Weikersthal
AU  - Thomas Decker
AU  - Florian Kaiser
AU  - Jens Uhlig
AU  - Michael Schenk
AU  - Jens Freiberg-Richter
AU  - Bettina Peuser
AU  - Claudio Denzlinger
AU  - Ullrich Graeven
AU  - Kathrin Heinrich
AU  - Swantje Held
AU  - Arndt Stahler
AU  - Annabel Helga Sophie Alig
AU  - Ivan Jelas
AU  - Jobst C. von Einem
AU  - Sebastian Stintzing
AU  - Clemens Giessen-Jung
AU  - Dominik P. Modest
PY  - 2022
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2022.751453
UR  - https://doi.org/10.3389/fonc.2022.751453
ER  -

APA

Kurreck, A., Heinemann, V., Weikersthal, L. F. V., Decker, T., Kaiser, F., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Graeven, U., Heinrich, K., Held, S., Stahler, A., Alig, A. H. S., Jelas, I., Einem, J. C. V., Stintzing, S., Giessen-Jung, C., & Modest, D. P. (2022). Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.751453

Source records

crossref · retrieved 2026-09-26T14:06:38.562Z